Psychedelics & Cannabis

While there are no FDA-approved medications available for CUD, some studies show potential off-label utility in mitigating withdrawal and maintaining abstinence. Learn more in this CME article.

From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.

From the unique challenges of treating physician-patients to updates on MDMA and psilocybin research and access, here are highlights from the week in Psychiatric Times.

A new bill, the Breakthrough Therapies Act, would encourage the reclassification of MDMA and psilocybin from schedule I to schedule II drugs.

The second of a phase 3 study examining MDMA-AT just completed its final participant visit.

A single dose of psilocybin could help patients with treatment-resistant depression, according to a new study.

Herbal medicines have been used to treat mental health disorders since ancient times, and continue to be useful today.

What is the effect of cannabis use on adherence to medications in patients with psychosis?

Classic psychedelic research is rapidly expanding...

Vol. 39, Issue 9 covers the latest in psychedelics research and development in psychiatry.

In a well-blinded study, researchers investigated and directly compared the acute effects of LSD and psilocybin in healthy participants.

How can a robust understanding of the altered-state experience drive the development of therapeutic frameworks that are designed around that experience?

The underlying neural mechanisms identified may help clinicians better understand ketamine response in human patients.

This new study is evaluating how effective psychedelics can be in the treatment of binge eating disorder.

Numinus' Chief Clinical Officer shares resources about the potential use of ketamine in psychiatry.

The first patient has been dosed in the phase 2b dose-optimization trial of a pharmaceutically optimized form of LSD for the treatment of generalized anxiety disorder.

This is the extra table for "Interest Grows in Treatment of Mood Disorders by Classic Psychedelics."

CBD and THC? What's the difference and why does it matter?

One researcher shares his evidence for the usage of psilocybin in psychiatry.

The resistance against "magic mushrooms"—is it justified?

We have an urgent need for new and improved treatment options for depression—are psychedelic medications the answer?

Cannabis use disorder and nonadherence: How can we best educate patients?

In honor of National CBD Day, Psychiatric Times™ shares some recent expert discussions on the pros, cons, and clinical implications of cannabis use in psychiatry.

Treatments alter the neural processes underlying SAD symptoms.